Table1 Clinical characteristics of the two immunotherapy cohorts.

From: Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB

 

MSKCC cohort

Validation cohort

No. of patients

350

256

Age

21–50

34 (9.7%)

27 (10.5%)

50–60

75 (21.4)

64 (25.0%)

61–70

119 (34.0%)

86 (33.6%)

> 70

122 (34.8%)

79 (30.9%)

Gender (%)

Female

180 (51.4%)

130 (50.7%)

Male

170 (48.5%)

126 (49.2%)

Sample type

Primary

171 (48.8%)

NA

Metastasis

179 (51.1%)

NA

TMB

High

112 (32%)

86 (33.6%)

Low

238 (68%)

170 (66.4%)

Drug type

Monotherapy (PD-1/PDL-1)

329 (94.0%)

206 (80.4%)

Combination (CTLA4 and PD-1/PDL-1)

21 (6.0%)

34 (13.2%)

Unknown

0

16 (6.2%)

OS status

Living

131 (37.4%)

NA

Deceased

219 (62.5%)

NA

PFS status

Progressed

NA

46 (17.9%)

Not progressed

NA

210 (82%)

Back to article page